Fezolinetant

Fezolinetant, marketed as Veozah, represents a new class of non-hormonal hot flash treatment approved by the FDA in 2023. It works through a completely different mechanism than hormone replacement therapy or older non-hormonal options. Understanding how fezolinetant works, what evidence supports it, and what safety considerations matter helps you evaluate whether it might be right for you.

The Neurokinin System and Hot Flashes

Hot flashes don't have a single, fully understood cause. Temperature regulation involves multiple brain centers, particularly the hypothalamus. This brain region contains neurons sensitive to temperature and controls your thermoregulatory responses like sweating and blood vessel dilation.

Research over the past decade has identified neurokinin receptors, particularly the NK3 receptor, as important in hot flash generation. These receptors are activated by neurokinin ligands, molecules your brain produces. The NK3 receptors are present in the hypothalamus and related brain regions involved in temperature control.

During menopause, the declining estrogen appears to increase activity of the neurokinin system. Additionally, estrogen withdrawal alters neurotransmitter systems in ways that increase heat sensitivity and sweating responses. The NK3 receptor appears central to this process. Blocking NK3 receptors interrupts the pathway driving hot flashes.

How Fezolinetant Works

Fezolinetant is a selective antagonist of the NK3 receptor. This means it blocks the NK3 receptor specifically, without significantly affecting other neurokinin receptors or other brain receptors. The selectivity reduces off-target effects and side effects compared to less selective antagonists.

By blocking NK3 receptors in the hypothalamus and related regions, fezolinetant reduces the neural signals driving hot flashes. It doesn't replace hormones. It doesn't work through hormonal mechanisms. It works purely by interrupting a specific neural pathway.

This mechanism differs fundamentally from hormone replacement therapy, which works by providing the missing hormones. It also differs from SSRIs and gabapentin, which work through broader effects on neurotransmitter systems.

Clinical Evidence

Fezolinetant was studied in two large randomized, placebo-controlled trials called SKYLIGHT 1 and SKYLIGHT 2. Both trials enrolled menopausal women with moderate to severe hot flashes and followed them for 12 weeks of treatment.

Results showed that fezolinetant reduced moderate to severe hot flashes by roughly 60 to 75 percent compared to about 30 to 40 percent reduction in placebo groups. This represented meaningful improvement, though not the 80 to 90 percent reduction seen with hormone replacement therapy.

Night sweats similarly improved, with fezolinetant reducing night sweats by roughly 50 to 70 percent. The improvement developed over one to two weeks and continued throughout the treatment period.

Additionally, fezolinetant appeared to improve quality of life and sleep quality measures. Women reported feeling better overall, not just having fewer hot flashes.

Importantly, the benefit was consistent across different ages and races of menopausal women studied, suggesting the medication works broadly rather than just for specific subgroups.

Dosing

Fezolinetant is taken as an oral tablet at a dose of 30 milligrams once daily. A lower dose of 15 milligrams was tested but showed less consistent benefit. The 30-milligram daily dose became the approved dose.

The medication is taken consistently, not cyclically. You take the same dose every day without breaks. It reaches steady-state effects after several days to a week of consistent use.

Side Effects and Tolerability

In clinical trials, fezolinetant was generally well tolerated. The most common side effects were gastrointestinal: nausea, constipation, and dry mouth occurred more frequently than in placebo groups, though absolute percentages remained modest. Most women tolerated the medication without these side effects.

Dizziness, headache, and insomnia occurred slightly more often than in placebo groups but remained uncommon.

Importantly, serious adverse events were rare and occurred at similar rates between fezolinetant and placebo groups, suggesting the medication wasn't associated with serious safety signals in the study populations.

The Liver Safety Consideration

A significant development came after FDA approval. Post-marketing experience revealed rare but serious cases of liver injury in women taking fezolinetant. Some women developed elevated liver enzymes indicating liver damage. A few cases were severe enough to warrant hospitalization.

This led the FDA to issue a warning that fezolinetant requires liver function monitoring. Current recommendations include checking liver enzymes before starting fezolinetant, then periodically during treatment, particularly in women with underlying liver disease or risk factors for liver problems.

This liver safety concern doesn't contraindicate fezolinetant in women with normal liver function, but it does mean monitoring is necessary. Women with known liver disease should not use fezolinetant without careful consideration. Women taking other medications that affect the liver should discuss whether fezolinetant is safe for them.

The liver concern also means fezolinetant is less convenient than initially hoped. You can't simply take it without medical oversight; you need regular blood work monitoring.

Who Is Fezolinetant For

Fezolinetant is intended for women with moderate to severe hot flashes who either cannot take hormone replacement therapy, don't want hormone therapy, or haven't had adequate response to other treatments. It's particularly valuable for women with contraindications to estrogen therapy, such as women with active breast cancer or women who had breast cancer relatively recently and aren't candidates for hormone therapy.

It's also an option for women whose hot flashes persist despite hormone replacement therapy, though this is less common.

Women with mild hot flashes might not experience enough benefit to justify the medication and required monitoring. Women with severe hot flashes might find fezolinetant's 60 to 75 percent improvement adequate, though they might prefer hormone replacement if they're candidates.

Comparison to Other Non-hormonal Options

Before fezolinetant, the non-hormonal options for hot flashes were SSRIs, SNRIs, and gabapentin. These medications reduce hot flashes by roughly 40 to 60 percent, less reliably than fezolinetant's 60 to 75 percent.

Fezolinetant's advantage is better efficacy and a cleaner mechanism. SSRIs and gabapentin work through multiple mechanisms and have broader effects throughout the brain and body. This explains why they have more varied side effects across different women.

Fezolinetant's disadvantage is the need for liver monitoring and the liver safety concern. SSRIs, SNRIs, and gabapentin have established long-term safety profiles. Fezolinetant is newer, and long-term safety data are still accumulating.

For women already on SSRIs or gabapentin and having good response, continuing these medications is reasonable. For women just starting non-hormonal treatment, fezolinetant is now an option to consider alongside SSRIs and gabapentin.

Cost and Access

Fezolinetant is relatively new to the market, and cost may be higher than older treatments. Insurance coverage varies. Some insurance plans cover it; others don't. Prior authorization may be required.

The monitoring requirement also adds cost and complexity. Regular liver function tests aren't expensive individually, but they require office visits and lab work, adding to overall cost compared to medications that don't require monitoring.

Combination Use

Can fezolinetant be combined with hormone replacement therapy? This question isn't fully addressed in the clinical trials. Theoretically, they work through different mechanisms and could be combined for women who want both approaches. However, they've not been specifically studied in combination, and combining them isn't standard practice yet.

Women on hormone replacement therapy with residual hot flashes might potentially add fezolinetant, but this would be an off-label combination not yet formally studied.

The Bigger Picture

Fezolinetant's approval represents the first new mechanism for hot flash treatment in years. It offers women a genuine alternative to hormone replacement therapy and older non-hormonal medications. For some women, it's a game-changer, offering better hot flash control than the options available before.

For others, the liver monitoring requirement and need for regular medical oversight makes hormone replacement therapy or older non-hormonal options more appealing.

The emerging understanding of the neurokinin system in hot flashes also opens the possibility for future medications in this class, potentially with better tolerability or efficacy. Elinzanetant, a related medication, is also in development and shows promise.

Fezolinetant represents a genuine advance in non-hormonal menopause treatment options, though like all treatments, it's not ideal for everyone. Understanding its mechanism, efficacy, and safety profile helps you evaluate whether it's worth considering for your particular situation.